Overview

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether oral rucaparib is effective in the treatment of patients with locally advanced or metastatic pancreatic cancer and a known deleterious BRCA mutation.
Phase:
Phase 2
Details
Lead Sponsor:
Clovis Oncology, Inc.
Treatments:
Rucaparib